Phase 2 N=121 A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Number of Participants With Adverse Events (AEs) — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=312 A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Number and Percentage of Subjects Who Achieved a Response at Week 24 According to the Modified British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus…
Phase 2 N=36 A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
T-cell Acute Lymphoblastic Leukemia · T-cell Lymphoblastic Lymphoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 2; 2; 3 Participants
Phase 2 N=84 Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
Lung Cancer
Primary: Overall Survival and Progression Free Survival — 29; 12.9; 22 percentage of participants
Phase 2 N=104 Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)
Alcoholic Hepatitis (AH)
Primary: Percentage of Participants With Treatment-Emergent (TE) Adverse Events (AE), Serious AEs (SAE), AEs Leading to Premature Study Drug Discontinuation, and Grade 3 or 4…
Phase 2 N=22 Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
Recurrent Glioma
Primary: Number of Participants With Adverse Events — 0; 1; 3; 3 Participants
Phase 2 N=50 Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease
Chronic Graft Versus Host Disease
Primary: Incidence of Adverse Events — 19; 18 participants
Phase 2 N=11 Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis
Fibrillary Glomerulonephritis
Primary: Change in 24 Hour Creatinine Clearance — 41.0 mL/min/SA — p=0.072
Phase 2 N=20 Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease
Chronic Graft Versus Host Disease
Primary: Incidence of Adverse Events — 8; 7 participants
Phase 2 N=83 Eribulin in HER2 Negative Metastatic BrCa
Breast Cancer
Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
Phase 2 N=171 BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
Psoriasis
Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A) — 1.7; 75.9; 74.5 percentage of…
Phase 2 N=35 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Phase 2 N=156 Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
Extensive Stage Small Cell Lung Carcinoma · Large Cell Lung Carcinoma · Neuroendocrine Carcinoma
Primary: Recommended Phase II Dose (Phase I) — 100 mg
Phase 2 N=24 Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Recurrent Mycosis Fungoides and Sezary Syndrome · Refractory Mycosis Fungoides and Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7
Primary: Objective Response Rate (ORR), Defined as a Confirmed Partial Response (PR) or Complete Response (CR) Using Global Assessment Standard Response Criteria for Mycosis…
Phase 2 N=13 Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Nephropathy
Primary: Change From Baseline to Week 6 in Endothelial Function — 1.44; 0.69 % diameter change — p=0.51